9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
104 hedge funds and large institutions have $76.6M invested in 9 Meters Biopharma in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 33 increasing their positions, 27 reducing their positions, and 14 closing their positions.
23% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $1.2M
22% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 27
1% less funds holding
Funds holding: 105 → 104 (-1)
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
19% less capital invested
Capital invested by funds: $94.2M → $76.6M (-$17.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$1.91M |
| 2 |
BlackRock
New York
|
+$669K |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$559K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$539K |
| 5 |
Two Sigma Investments
New York
|
+$354K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.04M |
| 2 |
Millennium Management
New York
|
-$646K |
| 3 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$619K |
| 4 |
D.E. Shaw & Co
New York
|
-$472K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$411K |
NMTR Hedge Fund Activity: Q4 2021 in Review
104 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q4 2021, worth a combined $76.6M — down 19% from $94.2M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of NMTR and 13 opened new positions — a net loss of 1 holder — while 27 trimmed existing stakes and 33 added.
The largest buyer was OrbiMed, adding an estimated $1.91M. The largest seller was Deutsche Bank, cutting an estimated $1.04M.
- 104 institutional investors held 9 Meters Biopharma (NMTR) as of Q4 2021, down from 105 in Q3 2021.
- Funds reported $76.6M of 9 Meters Biopharma stock for Q4 2021, down 19% quarter-over-quarter.
- 13 funds opened new 9 Meters Biopharma positions in Q4 2021 and 14 closed out, a net change of -1 holder.
- The largest 9 Meters Biopharma buyer in Q4 2021 was OrbiMed, an estimated $1.91M added.
- The largest 9 Meters Biopharma seller in Q4 2021 was Deutsche Bank, an estimated $1.04M sold.
Based on aggregated 13F filings for Q4 2021.